Alexandra Zeltsi

Alexandra Zeltsi

Auto-generated profile, based on publicly available information

Alexandra Zeltsi

Information Technologies Institute CERTH

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
RCRachel R Copland
Rachel R Copland
Sten HankeSten Hanke
Sten Hanke
ARAmy Rogers
Amy Rogers
Lampros MpaltadorosLampros Mpaltadoros
Lampros Mpaltadoros
Ioulietta LazarouIoulietta Lazarou
Ioulietta Lazarou
IMIsla S Mackenzie
Isla S Mackenzie
Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools to support trial activities and streamline trial processes. In particular, digital platforms with a modular architecture lend themselves to DCTs, where individual trial activities can correspond to specific platform modules. While design features can allow users to customize their platform experience, the real strengths of digital platforms for DCTs are enabling centralized data capture and remote monitoring of trial participants and in using digital technologies to streamline workflows and improve trial management. When selecting a platform for use in a DCT, sponsors and investigators must consider the specific trial requirements. All digital platforms are limited in their functionality and technical capabilities. Integrating additional functional modules into a central platform may solve these challenges, but few commercial platforms are open to integrating third-party components. The lack of common data standardization protocols for clinical trials will likely limit the development of one-size-fits-all digital platforms for DCTs. This viewpoint summarizes the current role of digital platforms in supporting decentralized trial activities, including a discussion of the potential benefits and challenges of digital platforms for investigators and participants. We will highlight the role of the digital platform in the development of DCTs and emphasize where existing technology is functionally limiting. Finally, we will discuss the concept of the ideal fully integrated and unified DCT and the obstacles developers must address before it can be realized.

20 September 2024
Verified
Book Chapter
Closed access
PDF file
AZAlexandra Zeltsi
Alexandra Zeltsi
MTMaria Tsourma
Maria Tsourma
AAAnastasios Alexiadis
Anastasios Alexiadis
AMAthanasios Mavropoulos
Athanasios Mavropoulos
AZAlexandros Zamichos
Alexandros Zamichos
Thanos StavropoulosThanos Stavropoulos
Thanos Stavropoulos

6 April 2023 in JMIR Preprints
Verified
Preprint
Open access
RCRachel R Copland
Rachel R Copland
Sten HankeSten Hanke
Sten Hanke
ARAmy Rogers
Amy Rogers
Lampros MpaltadorosLampros Mpaltadoros
Lampros Mpaltadoros
Ioulietta LazarouIoulietta Lazarou
Ioulietta Lazarou
IMIsla S Mackenzie
Isla S Mackenzie
UNSTRUCTURED Decentralized clinical trials (DCTs) are becoming increasingly popular. Digital clinical trial platforms are software environments where users complete designated clinical trial tasks, providing investigators and trial participants with efficient tools to support trial activities and streamline trial processes. In particular, digital platforms with a modular architecture lend themselves to DCTs, where individual trial activities can correspond to specific platform modules. While design features can allow users to customize their platform experience, the real strengths of digital platforms for DCTs are enabling centralized data capture and remote monitoring of trial participants and in using digital technologies to streamline workflows and improve trial management. When selecting a platform for use in a DCT, sponsors and investigators must consider the specific trial requirements. All digital platforms are limited in their functionality and technical capabilities. Integrating additional functional modules into a central platform may solve these challenges, but few commercial platforms are open to integrating third-party components. The lack of common data standardization protocols for clinical trials will likely limit the development of one-size-fits-all digital platforms for DCTs. This viewpoint summarizes the current role of digital platforms in supporting decentralized trial activities, including a discussion of the potential benefits and challenges of digital platforms for investigators and participants. We will highlight the role of the digital platform in the development of DCTs and emphasize where existing technology is functionally limiting. Finally, we will discuss the concept of the ideal fully integrated and unified DCT and the obstacles developers must address before it can be realized.